التفاصيل البيبلوغرافية
| العنوان: |
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. |
| المؤلفون: |
Solante, Rontgene, Alvarez-Moreno, Carlos, Burhan, Erlina, Chariyalertsak, Suwat, Chiu, Nan-Chang, Chuenkitmongkol, Sunate, Dung, D. V., Hwang, Kao-Pin, Ortiz Ibarra, Javier, Kiertiburanakul, Sasisopin, Kulkarni, Prasad S., Lee, Christopher, Lee, Ping-Ing, Lobo, Rommel Crisenio, Macias, Alejandro, Nghia, Cao Huu, Ong-Lim, Anna Lisa, Rodriguez-Morales, Alfonso J., Richtmann, Rosana, Safadi, Marco Aurélio Palazzi |
| المصدر: |
Expert Review of Vaccines; 2023, Vol. 22 Issue 1, p1-16, 16p |
| مصطلحات موضوعية: |
BOOSTER vaccines, VACCINE effectiveness, COVID-19 vaccines, SARS-CoV-2 Omicron variant, LITERATURE reviews |
| مستخلص: |
COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Expert Review of Vaccines is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
